Lynn Macmaster, APRN
Psychiatric/Mental Health · Milford, CTNPI 1962070862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 37.5% of the total. 2025 is the largest year on record at $2,203, 4.8 times the $462 reported in 2021. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$669
- Neurocrine Biosciences, Inc.$584
- Johnson & Johnson$433
- Indivior Inc.$253
- plus $721 from 8 others
What the payments were for
- Food & beverage$6,217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $2,334 |
| AbbVie | 52 | $1,223 |
| Teva Pharmaceuticals USA, Inc. | 19 | $669 |
| Neurocrine Biosciences, Inc. | 18 | $584 |
| Johnson & Johnson | 17 | $433 |
| Indivior Inc. | 10 | $253 |
| Otsuka America Pharmaceutical, Inc. | 8 | $246 |
| Alkermes, Inc. | 8 | $199 |
| Corium, LLC | 3 | $86 |
| E.r. Squibb & Sons, L.L.C. | 2 | $56 |
| Lundbeck LLC | 2 | $48 |
| Tris Pharma Inc | 1 | $45 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$1,298
- INGREZZA$236
- VRAYLAR$230
- Austedo XR$126
- REXULTI$125
- INVEGA SUSTENNA$118
- AUSTEDO$112
How this compares
$6,217 in reported general payments places this provider in the 90th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 28 | $40,251 |
| VraylarCariprazine Hcl | 25 | $34,915 |
| VivitrolNaltrexone Microspheres | 12 | $21,325 |
| AbilifyAripiprazole | 14 | $13,181 |
| TrintellixVortioxetine Hydrobromide | 25 | $11,821 |
| Clozapine | 140 | $6,992 |
| Duloxetine Hcl | 177 | $5,538 |
| Fluphenazine Hcl | 51 | $5,131 |
| Clozapine OdtClozapine | 12 | $4,595 |
| Perphenazine | 80 | $4,336 |
| Aripiprazole | 77 | $4,252 |
| Divalproex Sodium ErDivalproex Sodium | 56 | $2,400 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,979 |
| Mirtazapine | 90 | $1,964 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 13 | $1,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $246 | $40,25128 claims |
| AbbVieVraylar | $1,223 | $34,91525 claims |
| Alkermes, Inc.Vivitrol | $199 | $21,32512 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $56 | $13,18114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in Milford
- Patrick GagnonMilford$15K
- Genna ThompsonMilford$7K
- Sheila OppenheimerMilford$4K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.